Abstract Number: 1210 • ACR Convergence 2023
Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis
Background/Purpose: Data suggest that patient satisfaction with drug therapy in psoriasis (Pso) and psoriatic arthritis (PsA) is associated with treatment compliance and, ultimately, disease response.…Abstract Number: 1441 • ACR Convergence 2023
Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
Background/Purpose: Clinical improvements through Week (Wk)96, with no unexpected safety findings, have previously been reported with bimekizumab (BKZ) in the BE RADIANT phase 3b trial…Abstract Number: 1709 • ACR Convergence 2023
Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…Abstract Number: 2255 • ACR Convergence 2023
Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Background/Purpose: Psoriatic lesions in highly visible areas, including the nails, disproportionately affect patients' health‑related quality of life.[1] Here, we compare the efficacy of bimekizumab (BKZ)…Abstract Number: 106 • 2023 Pediatric Rheumatology Symposium
Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma
Background/Purpose: Juvenile localized scleroderma (LS) and systemic sclerosis (SSc) are rare rheumatic diseases often associated with severe morbidities. Delays in diagnosis are common, putting children…Abstract Number: 054 • 2023 Pediatric Rheumatology Symposium
Craniofacial Localized Scleroderma: A Single Center Retrospective Cohort
Background/Purpose: Craniofacial localized scleroderma (LS) can lead to disfigurement and severe extracutaneous manifestations (ECMs). There is an ongoing need to standardize multidisciplinary evaluation and care.…Abstract Number: L02 • ACR Convergence 2022
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…Abstract Number: 0161 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. Lenabasum, a non-psychoactive cannabinoid type 2 receptor (CB2R) agonist, is…Abstract Number: 0208 • ACR Convergence 2022
Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)
Background/Purpose: Retrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in DM, as measured by CDASI-A.…Abstract Number: 0209 • ACR Convergence 2022
Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis
Background/Purpose: Variations of the Investigator Global Assessment (IGA) of overall skin disease have been successfully used as a primary efficacy endpoint in registrational clinical trials…Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…Abstract Number: 0645 • ACR Convergence 2022
Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a manifestation of systemic lupus erythematosus (SLE) that can cause significant patient distress and disfiguration secondary to scar. Scarring…Abstract Number: 0662 • ACR Convergence 2022
Partial Correlations Network Models Show Th1, Th2 and Th17 Responses to Be Interlinked in Dermal Pathogenesis of Cutaneous Lupus Erythematous
Background/Purpose: The immunopathogenesis of cutaneous lupus erythematous (CLE) is highly diverse and involves activity of many different cell types and pathways. This heterogeneity is believed…Abstract Number: 0667 • ACR Convergence 2022
Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups
Background/Purpose: First-line treatment for cutaneous lupus erythematosus involves the use of antimalarials. Treatment response is highly variable with some patients responding well to hydroxychloroquine (HCQ),…Abstract Number: 0974 • ACR Convergence 2022
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype…
ACR Meeting Abstracts